Symptoms for neuroendocrine tumours (NETs) include fatigue, flushing, heart palpitations, an upset stomach and bowel symptoms.
Unfortunately NETs are difficult to diagnose because the symptoms are common across many illnesses, and treatments vary depending on where the tumour is located, how many there are, pace of growth and more.
The Hospital Research Foundation Group is proud to support the Nuclear Medicine Department at The Queen Elizabeth Hospital as a leader in the treatment of neuroendocrine tumours by providing patients access to world-leading clinical trials and research.
Neuroendocrine Tumour Support
Supporting The Queen Elizabeth Hospital’s nuclear medicine and oncology teams to offer Lutate Therapy (also known as Peptide Receptor Radionuclide Therapy PRRT) for patients with progressive neuroendocrine tumours.
From 2021, THRF has supported a Research Fellow to establish and develop the CALHN Sponsored Registry Electronic Data Registry (REDCAP ™) platform that captures data for South Australian patients treated with PRRT. More than 200 patients have received this treatment at TQEH since 2011 and ongoing support from THRF will ensure that this registry continues to be maintained and an important link into other service registries nationally.
A/Prof Gabrielle Cehic AM (left) and her team are passionate about supporting patients through their NET journey and improving future care.
THRF Funding has enabled a dedicated oncology-trained Clinical Nurse Consultant to join this team. Jessica Mercurio (middle) coordinates the wellness and survivorship program for patients. This is unique to each patient and focuses on education, self-management and wellbeing. Our patients and their carers have repeatedly expressed how supportive this program has been in reducing anxiety associated with a complex treatment regime.
